This treatment may be particularly important in variant carriers, given our previous report that HLHS patients with MYH6 variants have decreased cardiac transplant-free survival compared to HLHS patients without MYH6 variants [8]. This evidence concerns the gene MYH6 and hypoplastic left heart syndrome.